NeuroVive extends partnership agreement with InVentiv Health to prepare for upcoming market launch

Agreement expands consulting services acquired by NeuroVive, with the
possibility of a broader partnership for development and commercialization
services.
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company
specializing in drugs that treat acute cardiovascular and neurological
conditions, extends the partnership agreement with inVentiv Health, an important
strategic partner that offers best-in-class clinical, commercial and consulting
services.

NeuroVive, with a promising portfolio of mitochondrial drugs in development to
treat acute cardiovascular and neurological conditions, has been evaluating
various collaborations with large pharmaceutical companies and contract research
organizations to reduce risk and increase cost efficiencies. The company is
currently in the planning stage for commercialization of its lead product,
CicloMulsion®, now in a Phase III study to determine the drug’s effectiveness in
reducing cardiac damage following stenting in heart attack patients.

inVentiv Health works with pharmaceutical and biotechnology firms to help define
innovative alternatives to traditional development and commercialization models.
inVentiv offers mid-size pharmaceutical and biopharmaceutical companies an
expansive set of services that run from early-stage clinical development to full
global commercialization. The breadth of inVentiv Health’s services is unique in
the industry and includes comprehensive drug development, risk management,
market access and reimbursement, launch, marketing communications, payer
relations and patient outcomes.

NeuroVive is looking for a partner with an alternative business model that can
commercialize CicloMulsion® and be leveraged to scale for future products. By
working with inVentiv, the company will be able to maintain more control and
value while moving faster to market.

”We are very pleased to extend the collaboration with inVentiv Health, an
important step in preparing the market for launch of CicloMulsion® in Europe
and, later, in the United States,” said Mikael Brönnegård, CEO of NeuroVive
Pharmaceutical AB. “inVentiv Health´s commercial services will provide a
valuable platform for optimal market penetration at later stages and when
approaching the launch and marketing of the product.”

NeuroVive recently completed a one-year regulatory consulting project with
ParagonRx, inVentiv’s risk mitigation service. inVentiv will next be providing
market assessment services through its consulting arm, Campbell Alliance.
Campbell, a leading health care consulting firm, helps companies sell more
effectively in an environment increasingly dominated by third-party payers. The
work will start immediately with an assessment of the US market and a
continuation of the prelaunch activities and a plan for the market introduction
in Europe.

NeuroVive and inVentiv also are discussing a broader expansion of the
partnership to include future development and commercialization services for
CicloMulsion®.

“We’re big enough to step in and provide NeuroVive with virtually any service
they require to develop and commercialize their compound, and we’re flexible
enough to align with whatever they need to achieve their objectives,” said Dan
Feldman, President of inVentiv Health Europe. “Pharmaceutical companies face a
far more challenging market environment than ever before. Today’s market
requires innovative strategic partnerships. inVentiv Health was created to
provide this new model for the new marketplace.”

About NeuroVive
NeuroVive Pharmaceutical AB (publ), a leading mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of anti-viral indications
(Hepatitis B/C), brain cell injury in stroke patients, and drug candidates for
cellular protection and treating mitochondria-related energy regulation
diseases. NeuroVive’s shares are listed on NASDAQ OMX, Stockholm, Sweden.

About inVentiv Health
InVentiv Health´s broad range of services and global scale, represented by
approximately 12,000 employees supporting clients in more than 70 countries,
allow the firm to serve as a critical strategic partner for pharmaceutical,
biotechnology, medical device and diagnostics, and healthcare companies in their
dynamic and rapidly changing regulatory and commercial environments. InVentiv
Health serves more than 550 client organizations, including all 20 of the
largest global pharmaceutical companies. For more information, visit
www.inVentivHealth.com.

Media and investor relations questions to:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 6221 or ir@neurovive.se
Please also use the above contact if you wish to arrange an interview with
NeuroVive’s CEO, Mikael Brönnegård.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden, Tel: +46 (0)46 275 6220 (switchboard),
Fax: +46 (0)46 888 8348, info@neurovive.se, www.neurovive.se

inVentiv Health, Inc.
Danielle DeForge, Director, Corporate Communications, +1 781 425 4624,
Danielle.DeForge@inVentivhealth.com

[image]

NeuroVive Pharmaceutical AB (publ) is obligated to publish the information
contained in this news release in accordance with the Swedish Securities Market
Act. This information was provided to the media for publication at 13:00 CEST on
29 January 2014.